Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan | Financial Buzz

Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan

Cerveau Technologies Inc. today announced an agreement with the Kobe
City Hospital Organisation in Japan to support multiple projects over
the next several years. These research projects are for studies of an
early stage imaging agent (MK-6240) to be used in Positron Emission
Tomography (PET) scans for assessing the status and progression of
neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated
tau protein are a hallmark of several neurodegenerative diseases,
including Alzheimer’s disease.

As part of the agreement, Cerveau will contract with Kobe City Hospital
Organisation to manufacture and supply the [18F]MK-6240
needed for initiatives in the Kansai area.

According to Dr. Michio Senda, MD, PhD, Director of Molecular Imaging at
Kobe City Medical Center General Hospital (KCGH), which is managed by
Kobe City Hospital Organization (KCHO), “Tau-PET imaging is an excellent
tool of visualizing and evaluating neurofibrillary tangles in the living
human brain affected by Alzheimer’s disease, tauopathies, or other brain
disorders. It is also valuable for clinical trials of therapeutic drugs
for those diseases, which will be facilitated in Japan by the
collaboration with Cerveau.”

“Cerveau welcomes this opportunity to work with the Kobe City Hospital
Organisation (KCHO) which has developed a significant expertise in the
production of novel PET tracers for research. This agreement will
facilitate the understanding of the application of MK-6240 and how it
may benefit patients with brain diseases. Cerveau is investing
significantly in technologies, including novel PET Imaging biomarkers
and informatics, to help combat neurodegenerative disease and are
looking forward to a long term relationship with KCHO to help achieve
our collective visions. The collaboration with KCHO will provide further
access to our pharmaceutical partners in support of various therapy
trials and support our global production network in Europe, Canada,
Japan, China, Singapore, Australia and the United States,” said Rick
Hiatt, President and CEO of Cerveau Technologies, Inc.

About Kobe City Hospital Organization (KCHO):

Kobe City Hospital Organization (KCHO) is a public body organized by
Kobe City, Japan, and manages Kobe City Medical Center General Hospital
(KCGH) and other hospitals. Molecular Imaging Department (PET research
center) of KCGH was originally established in 2001 within a small
research hospital named Institute of Biomedical Research and Innovation
(IBRI) and has been involved in clinical research and trials using
various PET drugs on pathophysiology, clinical pharmacology and patient
diagnosis and treatment evaluation. Triggered by the Japanese new
guidelines on microdosing, it implemented phase-I clinical trials of
amyloid PET drugs on Japanese subjects, which led to implementing
further PET clinical trials and establishing new GMP-compliant hot labs
to produce PET drugs for those trials. Since IBRI merged with the
neighboring hospital KCGH in 2017, the PET center has been operated by
the latter with the same staff and facility.

About Cerveau Technologies, Inc.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical
Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to
globally develop diagnostics and technology that positively impact
patients with neurodegenerative disorders including Alzheimer’s disease.

www.cerveautechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005395/en/